SEC Form SC 13D/A filed by Innovative Solutions and Support Inc. (Amendment)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

_____________________________________________________________________________

SCHEDULE 13D

(Rule 13d-101. Information to be Included in Statements Filed Pursuant to §240.13d-1(a) and

Amendments Thereto Filed Pursuant to §240.13d-2(a))

Under the Securities Exchange Act of 1934

(Amendment No. 1)^*

_____________________________________________________________________________

Innovative Solutions and Support, Inc. 

(Name of Issuer)

Common Stock, par value $0.001 per share 

(Title of Class of Securities)

45769N-10-5 

(CUSIP Number)

Estate of Geoffrey S. M. Hedrick

c/o Innovative Solutions and Support, Inc.

Attn: Christopher Scott Ginieczki, Personal Representative of Estate

720 Pennsylvania Drive

Exton, PA 19341 

(610) 646-9800   

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 9, 2023   

(Date of Event Which Requires Filing of This Statement)

_____________________________________________________________________________

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

*  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D/A

CUSIP 45769N-10-5

SCHEDULE 13D/A

CUSIP 45769N-10-5

SCHEDULE 13D

CUSIP 45769N-10-5

The following constitutes Amendment No. 1 (this “Amendment No. 1”) to the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on December 28, 2022 by the Reporting Persons (the “Original Schedule 13D”). This Amendment No. 1 amends the Original Schedule 13D as specifically set forth herein. Except as amended and supplemented by this Amendment No. 1, the Original Schedule 13D remains unchanged. Capitalized terms used herein and not otherwise defined in this Amendment No. 1 shall have the meanings set forth in the Original Schedule 13D.

Item 4. Purpose of Transaction.

Item 4 of the Original Schedule 13D is hereby amended by adding the following immediately at the end thereof:

This Amendment No. 1 reports a decrease in the Reporting Persons percentage of beneficial ownership of the outstanding shares of Common Stock of the Issuer since the date of the Original Schedule 13D.

Item 5. Interest in Securities of the Issuer.

Paragraphs (a), (b) and (c) of Item 5 of the Original Schedule 13D are hereby deleted in their entirety and replaced with the following:

(a)-(b)     The Reporting Persons may be deemed to beneficially own 1,652,207 shares of Common Stock of the Issuer, which represent approximately 9.47% of the outstanding Common Stock of the Issuer, based on 17,438,768 shares of Common Stock of the Issuer outstanding as of April 28 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023. The Reporting Persons have shared voting and dispositive power over the 1,652,207 shares of Common Stock of the Issuer, which were previously owned directly by Mr. Hedrick prior to his death and are now owned by the Estate. In addition, Mr. Ginieczki may be deemed to share voting and dispositive power over 20,948 shares of Common Stock of the Issuer that are held by the Ginieczki Family Trust, of which Mr. Ginieczki is a co-trustee.

(c)       On August 9, 2023, the Estate distributed an aggregate of 1,683,168 shares of Common Stock of the Issuer to three newly created trusts for separate beneficiaries of the Estate pursuant to Mr. Hedrick’s will. Mr. Ginieczki is not a trustee of any of the trusts and has no voting or dispositive power over the shares of Common Stock of the Issuer held by the trusts. During the past sixty (60) days, the Estate sold an aggregate of 174,372 shares of Common Stock of the Issuer in open market transactions as follows:

(1)       The price shown is the weighted average sale price for the transactions reported on this date. These shares of Common Stock were sold in multiple transactions at prices ranging from $7.10 to $7.39 per share, excluding commissions.

(2)        The price shown is the weighted average sale price for the transactions reported on this date. These shares of Common Stock were sold in multiple transactions at prices ranging from $7.25 to $7.50 per share, excluding commissions.

(3)       The price shown is the weighted average sale price for the transactions reported on this date. These shares of Common Stock were sold in multiple transactions at prices ranging from $7.36 to $7.56 per share, excluding commissions.

(4)       The price shown is the weighted average sale price for the transactions reported on this date. These shares of Common Stock were sold in multiple transactions at prices ranging from $7.80 to $8.10 per share, excluding commissions.

(5)       The price shown is the weighted average sale price for the transactions reported on this date. These shares of Common Stock were sold in multiple transactions at prices ranging from $7.40 to $7.72 per share, excluding commissions.

The Reporting Persons undertake to provide, upon request, to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Item 7.      Material to be Filed as Exhibits.

SIGNATURES

After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: August 11, 2023